{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T20:36:02Z","timestamp":1648672562462},"reference-count":0,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[1984,12,1]],"date-time":"1984-12-01T00:00:00Z","timestamp":470707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1984,12]]},"abstract":"<jats:p>The in vitro activity of CGP 31523A, a new aminothiazolyl cephalosporin, was compared with those of cefoxitin, cefuroxime, moxalactam, piperacillin, ciprofloxacin, and other beta-lactams, when appropriate, against 533 recent clinical isolates and known resistant strains of bacteria. The MICs of CGP 31523A required to inhibit 90% (MIC90S) of the members of the family Enterobacteriaceae, Neisseria gonorrhoeae, and Streptococcus pneumoniae were less than or equal to 0.25 micrograms\/ml. Of Staphylococcus aureus (excluding methicillin-resistant strains) and Haemophilus influenzae, 90% were susceptible to 0.5 micrograms\/ml. Pseudomonas aeruginosa and Lancefield group D streptococci were resistant to CGP 31523A (MIC90, greater than or equal to 128 micrograms\/ml). The activity against Bacteroides fragilis was modest (MIC90, 32 micrograms\/ml). The susceptibility of known beta-lactamase-producing strains suggested that CGP 31523A was resistant to many beta-lactamases (but not those of Bacteroides fragilis). The serum protein binding of CGP 31523A was about 73%. The primary target site of CGP 31523A in Escherichia coli appeared to be penicillin-binding protein 3.<\/jats:p>","DOI":"10.1128\/aac.26.6.876","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:03:40Z","timestamp":1340841820000},"page":"876-880","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["In vitro activity of CGP 31523A, a broad-spectrum cephalosporin, in comparison with those of other agents"],"prefix":"10.1128","volume":"26","author":[{"given":"R","family":"Wise","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.26.6.876","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.26.6.876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T14:37:45Z","timestamp":1645454265000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.26.6.876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,12]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1984,12]]}},"alternative-id":["10.1128\/AAC.26.6.876"],"URL":"https:\/\/doi.org\/10.1128\/aac.26.6.876","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,12]]},"assertion":[{"value":"1984-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}